Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.16B
Close$
$64.19
79.2% downside
Current Fair Value
79.2% downsideOvervalued by 79.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $6.16 Billion |
|---|---|
| Enterprise Value | $7.26 Billion |
| Earnings per Share | $6.44 |
| Beta | 1.04 |
| Outstanding Shares | 19,962,000 |
Return
| Return on Equity | 2.10% |
|---|---|
| Return on Assets | 0.90% |
| Return on Invested Capital | 7.06% |
Valuation & Multiples
| P/E Ratio | 119.22 |
|---|---|
| PEG | -75.88 |
| Price to Sales | 25.73 |
| Price to Book Ratio | 6.43 |
| Enterprise Value to Revenue | 28.61 |
| Enterprise Value to EBIT | 59.19 |
| Enterprise Value to Net Income | 358 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 1.2 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$2.26
Consensus analyst estimateRevenue Estimate
$77.95 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$2.84
Consensus analyst estimateRevenue Estimate
$97.80 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 85.43% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 22.98%▼ 90.79% |
|---|---|
| Total Invested | $1.44B▼ 80.04% |
| Investors Holding | 194▼ 238.00% |
About Ligand Pharmaceuticals, Inc.
47 employees
CEO: John Higgins
Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its...